Sex-Gender Differences in Diabetes Vascular Complications and
... e Malattie Metaboliche ASL 2 Olbia, Italy Abstract: Diabetes mellitus and cardiovascular diseases act as two sides of the same coin: diabetes is an important risk factor for cardiovascular disease while patients with ischemic cardiovascular diseases often have diabetes or pre-diabetes. As firstly sh ...
... e Malattie Metaboliche ASL 2 Olbia, Italy Abstract: Diabetes mellitus and cardiovascular diseases act as two sides of the same coin: diabetes is an important risk factor for cardiovascular disease while patients with ischemic cardiovascular diseases often have diabetes or pre-diabetes. As firstly sh ...
PPT - American Academy of Pediatrics
... Difference in A1C between CSII and MDI In 22 studies, severe hypoglycemia was reduced with CSII by a rate ratio of 2.89 for RCTs and 4.34 for before/after studies. The mean difference in A1C was 0.21% for RCTs and 0.72% for before/after studies, related to initial A1C (p<0.001). ...
... Difference in A1C between CSII and MDI In 22 studies, severe hypoglycemia was reduced with CSII by a rate ratio of 2.89 for RCTs and 4.34 for before/after studies. The mean difference in A1C was 0.21% for RCTs and 0.72% for before/after studies, related to initial A1C (p<0.001). ...
Obviating Much of the Need for Insulin Therapy in Type 2 Diabetes
... of cardiovascular (CV) disease. Striking associations between exogenous insulin and risks of CV events, cancer, and all-cause mortality in clinical trial and real-world cohorts caution that insulin may pose more harm than previously evidenced. At our disposal are numerous alternate tools that, alone ...
... of cardiovascular (CV) disease. Striking associations between exogenous insulin and risks of CV events, cancer, and all-cause mortality in clinical trial and real-world cohorts caution that insulin may pose more harm than previously evidenced. At our disposal are numerous alternate tools that, alone ...
Frequency of lipodystrophy induced by recombinant human insulin
... lipodystrophic lesion there was a relationship between the injection site and likely of developing insulin induced lipodystrophy6,9,11,12,20. Hauner et al6 evaluated the presence of the lipodystrophy more on the abdomen; conversely, in our study it was noticed more on the arm. The reason of this dif ...
... lipodystrophic lesion there was a relationship between the injection site and likely of developing insulin induced lipodystrophy6,9,11,12,20. Hauner et al6 evaluated the presence of the lipodystrophy more on the abdomen; conversely, in our study it was noticed more on the arm. The reason of this dif ...
"The United States was (and is) paying a
... on everyone who heard it. The most interesting comment I heard repeatedly after the talk was how “brave” I was to give such a transparent talk against the insulin companies. In reality, at the time, I did not have a good understanding of how the various “middlemen” or “drug channel companies” (pharm ...
... on everyone who heard it. The most interesting comment I heard repeatedly after the talk was how “brave” I was to give such a transparent talk against the insulin companies. In reality, at the time, I did not have a good understanding of how the various “middlemen” or “drug channel companies” (pharm ...
Initiating and Titrating Insulin Therapy
... be taken before meals for nutrient coverage. Recently published studies have compared the effects of adding basal versus prandial coverage in patients with type 2 diabetes on oral agents. The Treating to Target in Type 2 Diabetes study group found that, although prandial insulin improved A1C slightl ...
... be taken before meals for nutrient coverage. Recently published studies have compared the effects of adding basal versus prandial coverage in patients with type 2 diabetes on oral agents. The Treating to Target in Type 2 Diabetes study group found that, although prandial insulin improved A1C slightl ...
Unmet Needs in Hispanic/Latino Patients with Type 2 Diabetes
... ground of insulin resistance. The prevalence of the metabolic syndrome by sex and race/ethnicity, according to data from the National Health and Nutrition Examination Survey (NHANES) from 2003 to 2006, is summarized in Figure 1.11 The prevalence of individual metabolic abnormalities in Mexican Ameri ...
... ground of insulin resistance. The prevalence of the metabolic syndrome by sex and race/ethnicity, according to data from the National Health and Nutrition Examination Survey (NHANES) from 2003 to 2006, is summarized in Figure 1.11 The prevalence of individual metabolic abnormalities in Mexican Ameri ...
Study of diabetes in Dharwad- an urban area in India
... our study subjects who were diabetic and gave family 2011). In our study, among diabetics, women accounted for history of diabetes. about 60% (10/18). It differed from the earlier estimate Of the 58(55.8%) who performed physical exercise, 52(89.66%) were non-diabetic and was found to be that prevale ...
... our study subjects who were diabetic and gave family 2011). In our study, among diabetics, women accounted for history of diabetes. about 60% (10/18). It differed from the earlier estimate Of the 58(55.8%) who performed physical exercise, 52(89.66%) were non-diabetic and was found to be that prevale ...
Epidemiology of diabetes: prevalence, complications and health
... The worldwide prevalence of DM has risen dramatically over the past two decades, from an estimated 30 million cases in 1985 to 285 million in 2010. International Diabetes Federation projects that 438 million individuals will have diabetes by the year 2030 . ...
... The worldwide prevalence of DM has risen dramatically over the past two decades, from an estimated 30 million cases in 1985 to 285 million in 2010. International Diabetes Federation projects that 438 million individuals will have diabetes by the year 2030 . ...
Increased Mortality of Patients With Diabetes
... whether patient self-report of severe hypoglycemia is associated with increased mortality. RESEARCH DESIGN AND METHODSdAdult patients (N = 1,020) seen in a specialty diabetes clinic between August 2005 and July 2006 were questioned about frequency of hypoglycemia during a preencounter interview; 7 w ...
... whether patient self-report of severe hypoglycemia is associated with increased mortality. RESEARCH DESIGN AND METHODSdAdult patients (N = 1,020) seen in a specialty diabetes clinic between August 2005 and July 2006 were questioned about frequency of hypoglycemia during a preencounter interview; 7 w ...
Practical Applications of Insulin Pump Therapy in Type 2 Diabetes
... quentially at mealtimes to control postprandial glucose (“basal/bolus” regimen). Exhibit 6 illustrates both physiologic insulin secretion and an ideal basal and bolus dosing regimen of insulin.8 Intensive insulin regimens require at least four injections daily and may require up to seven injections. ...
... quentially at mealtimes to control postprandial glucose (“basal/bolus” regimen). Exhibit 6 illustrates both physiologic insulin secretion and an ideal basal and bolus dosing regimen of insulin.8 Intensive insulin regimens require at least four injections daily and may require up to seven injections. ...
IDF-DAR-Practical-Guidelines_Part_2
... each period of fasting may last for up to 20 hours. Fasting is mandatory for all Muslim adults, with certain groups exempted, such as those who are suffering with illness – this may include some individuals with diabetes. Because of the metabolic nature of the disease, patients with diabetes are at ...
... each period of fasting may last for up to 20 hours. Fasting is mandatory for all Muslim adults, with certain groups exempted, such as those who are suffering with illness – this may include some individuals with diabetes. Because of the metabolic nature of the disease, patients with diabetes are at ...
Pharmacology - 11-15
... Which of the following is true of Type II diabetes? a. It is caused by an autoimmune reaction b.It is caused by insufficient insulin production c. It is caused by decreased insulin sensitivity d.It is known as Insulin-Dependent Diabetes Mellitus ...
... Which of the following is true of Type II diabetes? a. It is caused by an autoimmune reaction b.It is caused by insufficient insulin production c. It is caused by decreased insulin sensitivity d.It is known as Insulin-Dependent Diabetes Mellitus ...
Medicines in Development for Diabetes
... While healthy eating and exercise can help prevent and manage type 2 diabetes, medicines play a key role in helping to treat and reduce the risk of the disease. Patient adherence to diabetes medications can lead to better health outcomes and reduced health care costs. One study estimates that improv ...
... While healthy eating and exercise can help prevent and manage type 2 diabetes, medicines play a key role in helping to treat and reduce the risk of the disease. Patient adherence to diabetes medications can lead to better health outcomes and reduced health care costs. One study estimates that improv ...
Diabetes: Media Factsheet
... with a single drug require the addition of a second drug after three years. After nine years, approximately 75% of patients need multiple therapies to achieve adequate glucose control.7 The goal of diabetes treatments is to achieve as close-to-normal blood glucose levels as possible. While guidance ...
... with a single drug require the addition of a second drug after three years. After nine years, approximately 75% of patients need multiple therapies to achieve adequate glucose control.7 The goal of diabetes treatments is to achieve as close-to-normal blood glucose levels as possible. While guidance ...
- Journal of the ASEAN Federation of Endocrine Societies
... T2DM cohorts, there were overall high rates of macrovascular and microvascular complications across all cohorts consistent with the observation on the aggressive nature of young-onset T2DM4,5,7(Table 5). Compared to the Joint Asia Diabetes Evaluation (JADE) cohort in Asia, our young-onset T2DM cohor ...
... T2DM cohorts, there were overall high rates of macrovascular and microvascular complications across all cohorts consistent with the observation on the aggressive nature of young-onset T2DM4,5,7(Table 5). Compared to the Joint Asia Diabetes Evaluation (JADE) cohort in Asia, our young-onset T2DM cohor ...
Meeting 5
... NHS Lothian To define outcome measures and the feasibility of data collection to inform a future RC prospective study evaluating the clinic To measure impact of outcome measures such as proportion of patients reaching BP target, proportion of quality standards reached for prescribing and hospital ...
... NHS Lothian To define outcome measures and the feasibility of data collection to inform a future RC prospective study evaluating the clinic To measure impact of outcome measures such as proportion of patients reaching BP target, proportion of quality standards reached for prescribing and hospital ...
Different Lipid Variables Predict Incident Coronary
... The result of this measurement was used in the multivariate analyses. Estimated glucose disposal rate (eGDR) was calculated with an equation developed by Williams et al. (14) modified for use with HbA1c instead of HbA1 (12). Serum lipid and lipoprotein concentrations were all measured centrally from ...
... The result of this measurement was used in the multivariate analyses. Estimated glucose disposal rate (eGDR) was calculated with an equation developed by Williams et al. (14) modified for use with HbA1c instead of HbA1 (12). Serum lipid and lipoprotein concentrations were all measured centrally from ...
DIABETES OVERVIEW AND UPDATE Barb Bancroft, RN, MSN, PNP
... 2 (darker skin increased melanin—decreased vitamin D ...
... 2 (darker skin increased melanin—decreased vitamin D ...
Diabetes Mellitus
... Prediabetes is a term used to distinguish people who are at increased risk of developing diabetes. People with prediabetes have impaired fasting glucose (IFG) or impaired glucose tolerance (IGT). Some people may have both IFG and IGT. IFG is a condition in which the fasting blood sugar level is elev ...
... Prediabetes is a term used to distinguish people who are at increased risk of developing diabetes. People with prediabetes have impaired fasting glucose (IFG) or impaired glucose tolerance (IGT). Some people may have both IFG and IGT. IFG is a condition in which the fasting blood sugar level is elev ...
A Variant of the Transcription Factor 7- Like 2
... OBJECTIVE — Posttransplantation diabetes mellitus (PTDM) is a major complication associated with kidney transplantation. Defects in insulin secretion play a pivotal role in the pathogenesis of PTDM. A polymorphism in the transcription factor 7-like 2 (TCF7L2) gene was reported to be associated with ...
... OBJECTIVE — Posttransplantation diabetes mellitus (PTDM) is a major complication associated with kidney transplantation. Defects in insulin secretion play a pivotal role in the pathogenesis of PTDM. A polymorphism in the transcription factor 7-like 2 (TCF7L2) gene was reported to be associated with ...
Slide 1
... A report from KSA suggested an increased incidence of retinal vein occlusion in patients who fasted during RAMADAN Hospitalization due to coronary events or stroke was not increased during RAMADAN ...
... A report from KSA suggested an increased incidence of retinal vein occlusion in patients who fasted during RAMADAN Hospitalization due to coronary events or stroke was not increased during RAMADAN ...
Marker for the diagnosis of an insulin resistance
... cell which is followed by an increased insulin need is called insulin resistance. The insulin resistance represents an important pathogeneic mechanism in the development of type 2 diabetes and is often already observed years before the manifestation, in the context of a metabolic syndrome. Beyond th ...
... cell which is followed by an increased insulin need is called insulin resistance. The insulin resistance represents an important pathogeneic mechanism in the development of type 2 diabetes and is often already observed years before the manifestation, in the context of a metabolic syndrome. Beyond th ...
Glycemic Management of Type 2 Diabetes: An Emerging Strategy
... secretion of gut peptides, such as glucagon-like peptide (GLP)-1 [22]. TZDs bind to the peroxisome-proliferator–activated receptor-c and the resulting complex alters expression of many genes. The best understood effects of this process are cellular replication and an increase of sensitivity to insuli ...
... secretion of gut peptides, such as glucagon-like peptide (GLP)-1 [22]. TZDs bind to the peroxisome-proliferator–activated receptor-c and the resulting complex alters expression of many genes. The best understood effects of this process are cellular replication and an increase of sensitivity to insuli ...
SD-16 Outline - American Academy of Optometry
... Kuniyoshi Kanai, O.D., F.A.A.O. Brian Wolff, O.D. Abstract: The diabetic eye contains a goldmine of information not only on the vascular integrity of the retina, but also on the rest of the body. There is increasing evidence in the literature that link diabetic retinopathy (DR) with other end-organ- ...
... Kuniyoshi Kanai, O.D., F.A.A.O. Brian Wolff, O.D. Abstract: The diabetic eye contains a goldmine of information not only on the vascular integrity of the retina, but also on the rest of the body. There is increasing evidence in the literature that link diabetic retinopathy (DR) with other end-organ- ...
Rosiglitazone
Rosiglitazone (trade name Avandia, GlaxoSmithKline) is an antidiabetic drug in the thiazolidinedione class of drugs. It works as an insulin sensitizer, by binding to the PPAR receptors in fat cells and making the cells more responsive to insulin. It is marketed by the pharmaceutical company GlaxoSmithKline (GSK) as a stand-alone drug or for use in combination with metformin or with glimepiride. First released in 1999, annual sales peaked at approximately $2.5-billion in 2006; however, following a meta-analysis published in the New England Journal of Medicine in 2007 that linked the drug's use to an increased risk of heart attack, sales plummeted to just $9.5-million in 2012. The drug's patent expired in 2012.Despite rosiglitazone's effectiveness at decreasing blood sugar in type 2 diabetes mellitus, its use decreased dramatically as studies showed apparent associations with increased risks of heart attacks and death. Adverse effects alleged to be caused by rosiglitazone were the subject of over 13,000 lawsuits against GSK; as of July 2010, GSK had agreed to settlements on more than 11,500 of these suits.Some reviewers recommended rosiglitazone be taken off the market, but an FDA panel disagreed, and it remains available in the U.S. From November 2011 until November 2013, the federal government did not allow Avandia to be sold without a prescription from a certified doctor; moreover, patients were required to be informed of the risks associated with its use, and the drug had to be purchased by mail order through specified pharmacies. In November 2013, the FDA lifted its earlier restrictions on rosiglitazone after reviewing the results of the 2009 RECORD clinical trial (a six-year, open label randomized control trial), which failed to show heart infarct risks associated with the drug.In Europe, the European Medicines Agency (EMA) recommended in September 2010 that the drug be suspended from the European market because the benefits of rosiglitazone no longer outweighed the risks. It was withdrawn from the market in the UK and India in 2010, and in New Zealand and South Africa in 2011.